SBC Medical (SBC) Q4 2025 earnings review
Transitional Year Ends with Strong Earnings Beat Amid Persistent Revenue Declines
SBC Medical's Q4 results show a stark divergence between top-line contraction and bottom-line expansion. Total revenue fell 11% YoY to $40 million, extending a streak of negative growth driven by strategic restructuring and a revised franchise fee model. However, net income surged 117% to $14 million, heavily benefiting from the absence of prior-year IPO-related stock-based compensation and impairment charges. While management insists the structural revenue headwinds are now largely in the rearview mirror, the 12-percentage-point compression in Q4 EBITDA margin to 34% indicates operational profitability has not fully stabilized. The long-term growth story remains intact with accelerating franchise expansion and an inflection in average revenue per user (ARPU).
🐂 Bull Case
The 117% YoY surge in Q4 Net Income proves the heavy IPO-related expenses ($13M stock-based comp, $15M impairments in FY24) are fully cleared. The company's net income margin expanded substantially from 15% to 36% in the fourth quarter.
Average revenue per customer reversed its gradual decline, climbing 11% YoY to $316 in Q4. This validates the effectiveness of SBC's recent pricing optimization and customer engagement initiatives.
🐻 Bear Case
Despite net income improvements, operational profitability took a hit. Q4 EBITDA margin dropped steeply by 12 percentage points to 34%, contradicting management's narrative of universally strengthened underlying profitability.
Revenue fell 11% to $40M, marking the fifth consecutive quarter of double-digit percentage declines. The revised franchise fee structures continue to limit immediate top-line realization.
⚖️ Verdict: ⚪
Neutral. The business is fundamentally healthier after shedding bloated IPO expenses and unprofitable segments, but we need to see the promised 'sustainable top-line growth' materialize in FY26 before adopting a fully bullish stance. The recovery in ARPU is the strongest leading indicator.
Key Themes
ARPU Shows Reversing Trend
After several quarters of declining unit metrics, average revenue per customer recovered sharply to $316 in Q4, an 11% increase YoY. This reversing trend is a critical driver for future margin expansion, proving that strategic pricing changes implemented earlier in the year are finally sticking with consumers.
Relentless Franchise Network Expansion
Operational metrics entirely decoupled from the declining revenue figures. SBC ended FY25 with 283 franchise locations, an accelerating addition of 34 clinics YoY (a jump from 258 in Q3). Consequently, the LTM customer base grew 12% to 6.6 million, backed by a highly stable 72% repeat rate.
Multi-Brand and Technology Integration
SBC is aggressively pursuing specialized healthcare via its multi-brand strategy (Rize, Gorilla, JUN CLINIC) and expanding its non-aesthetic footprint. Prior partnerships, such as the B4A SaaS system integration and the tender offer for Waqoo Inc. (enhancing AGA and orthopedics), are laying the digital and operational groundwork for higher-margin specialized services.
EBITDA Margin Collapse Contradicts Optimism
Management highlighted that 'underlying profitability strengthened considerably.' However, the specific data point of Q4 EBITDA contradicts this: EBITDA fell 35% YoY to $14M, and EBITDA margin decelerated dramatically from 47% to 34%. This suggests that while net income improved due to a lack of one-off write-downs, core operational leverage is deteriorating under the new, lower-revenue franchise fee model.
Heavy Reliance on Related-Party Revenues
The company's revenue remains overwhelmingly concentrated in related-party transactions ($158.8M out of $173.6M in FY25, or 91%). While expected in a management services organization tied to specific medical corporations, it creates governance and cash-flow risks. Accounts receivable from related parties doubled YoY to $27.5M, a trend requiring tight monitoring for collection efficiency.
Macro Pressures: FX and Japanese Consumer Caution
Throughout FY25, management explicitly noted that Japan's consumer discretionary market faced restrained growth due to cautious consumer spending. Furthermore, FX volatility previously hit net income hard (e.g., Q2 25). If the Bank of Japan shifts policy and the yen fluctuates wildly, foreign exchange losses could repeatedly derail bottom-line predictability.
Other KPIs
Accelerating. Cash provided by operating activities increased by nearly 20% YoY from $20.58M in FY24. This was achieved despite a $31M drop in net revenue, underscoring effective working capital management and the non-cash nature of prior year charges.
Strong liquidity position, up from $125.0M at the end of FY24. The robust balance sheet provides ample ammunition for share repurchases (having bought back $5M+ during the year) and potential M&A in non-aesthetic healthcare spaces.
Guidance
Management opted out of providing explicit numerical guidance for FY26 revenue or earnings. They qualitatively guided for a 'return to sustainable top-line growth' as the structural headwinds from the April 2025 franchise fee revisions have now annualized. Investors should demand specific targets to underwrite the growth narrative.
Key Questions
EBITDA Margin Floor
With Q4 EBITDA margin dropping to 34% from 47% a year ago, where does management see the structural floor for margins under the new franchise fee arrangement?
Visibility on Revenue Growth
You stated the company is positioned to return to sustainable top-line growth in 2026. Can you quantify the expected organic growth rate of the existing clinic base versus growth derived from newly opened locations?
Related Party Receivables
Accounts receivable from related parties grew significantly this year. Are there any structural delays in cash collections from the managed medical corporations, and how are you managing that credit risk?
Capital Allocation and M&A
With $163M in cash on the balance sheet, how aggressive will SBC be in deploying capital toward the stated goal of expanding the non-aesthetic healthcare portfolio in 2026?